title: [Prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr among ESBL producing enterobacteria isolates from Chilean hospitals].
abstract: BACKGROUND
  The frequency of aac(6')-Ib-cr gene in ESBL-producing strains of Klebsiella pneumoniae and Escherichia coli is unknown, in Chile.
  
  
  METHODS
  The aac(6')-Ib and aac(6')-Ib-cr genes were investigated using polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), and sequencing, in strains isolated from 10 Chilean hospitals between 2008-2009.
  
  
  RESULTS
  The aac(6')-Ib-cr gene was detected in 54% of K. pneumoniae and 74% of E. coli strains. The CIM(50) of CIP was higher among strains harboring aac(6')-Ib-cr, 8 times higher in K. pneumoniae and 4 times higher in E. coli. Moreover, both aac(6')-Ib and aac(6')-Ib-cr were simultaneously found in 13 K. pneumoniae and 3 E. coli isolates.
  
  
  CONCLUSIONS
  This is the first report of aac(6')-Ib-cr in ESBL-producing strains of K. pneumoniae and E. coli isolated from in-patients in Chilean hospitals located along an area of more than 2,800 Km.
authors.affiliation: Departamento de Microbiología, Universidad de Concepción, Concepción, Chile.
authors.forename: Eliú
authors.initials: E
authors.lastname: Elgorriaga-Islas
authors.forename: Piero
authors.initials: P
authors.lastname: Guggiana-Nilo
authors.forename: Mariana
authors.initials: M
authors.lastname: Domínguez-Yévenes
authors.forename: Gerardo
authors.initials: G
authors.lastname: González-Rocha
authors.forename: Sergio
authors.initials: S
authors.lastname: Mella-Montecinos
authors.forename: Jaime
authors.initials: J
authors.lastname: Labarca-Labarca
authors.forename: Patricia
authors.initials: P
authors.lastname: García-Cañete
authors.forename: Helia
authors.initials: H
authors.lastname: Bello-Toledo
mesh_terms: D000107:Acetylation; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D002677:Chile / Q000453:epidemiology; D002939:Ciprofloxacin / Q000494:pharmacology; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D029968:Escherichia coli Proteins / Q000235:genetics* / Q000378:metabolism; D024841:Fluoroquinolones / Q000378:metabolism / Q000494:pharmacology*; D005798:Genes, Bacterial; D006801:Humans; D007710:Klebsiella Infections / Q000453:epidemiology / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D009268:Nalidixic Acid / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D012150:Polymorphism, Restriction Fragment Length; D011815:R Factors / Q000235:genetics*; D017422:Sequence Analysis, DNA; D013379:Substrate Specificity
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D024841:Fluoroquinolones; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D015242:Ofloxacin